Skip to main content
Hengrui Pharma logo

Hengrui Pharma — Investor Relations & Filings

Ticker · 600276 ISIN · CNE0000014W7 LEI · 2549003BT1XS3SE3E448 HKEX Manufacturing
Open in API
Filings indexed 2,704 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country CN China
Listing HKEX 600276

About Hengrui Pharma

https://www.hrs.com

Hengrui Pharma is an innovative, global pharmaceutical company focused on the research, development, manufacturing, and commercialization of medicines. The company specializes in therapies for oncology, surgical applications, and interventional imaging. With a strong commitment to R&D, Hengrui has developed and commercialized numerous new molecular entities and is expanding its portfolio to address unmet medical needs in international markets. Its core activities revolve around creating high-quality and accessible treatments, particularly in the field of cancer therapy.

Recent filings

Filing Released Lang Actions
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 82% confidence The document is an official announcement by Jiangsu Hengrui Pharmaceutical (stock code 600276) disclosing that its subsidiary received a clinical trial approval notification from the National Medical Products Administration. It contains no financial statements, no management discussion on quarterly/annual results, no shareholder vote, no capital changes, nor any of the other specific categories. This is a compliance/regulatory announcement, so it falls under the fallback category Regulatory Filings (RNS).
2026-05-26 Chinese
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 85% confidence The document is a standard corporate announcement about receiving a drug clinical trial approval notice from the National Medical Products Administration. It is not a financial report, dividend notice, earnings release, management change, or other specific category. It falls under general regulatory announcements and is a fallback type that does not fit other categories.
2026-05-26 Chinese
恒瑞医药差异化分红事项法律意见书
Regulatory Filings Classification · 96% confidence The document is a legal opinion (“法律意见书”) prepared by an outside law firm for Jiangsu Hengrui Pharmaceuticals regarding the legal compliance of a differentiated dividend distribution plan. It contains no financial statements or earnings, no management discussion, nor is it an investor presentation or dividend notice per se. Instead, it is a compliance/legal opinion letter intended for submission to the stock exchange. This falls under the fallback category of general regulatory/compliance filings. Therefore, it should be classified as Regulatory Filings (RNS).
2026-05-20 Chinese
恒瑞医药关于获得药品注册批准的公告
Regulatory Filings Classification · 40% confidence The document is an official announcement by the company’s board disclosing that its subsidiary received drug registration approval from the National Medical Products Administration. It is an operational/regulatory news release regarding product approval rather than a financial report, management change, capital structure update, or any specialized category. It does not contain financial statements or specific regulatory form references, so under the taxonomy it falls into the general “Regulatory Filings” fallback category (RNS).
2026-05-19 Chinese
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 75% confidence The document is a corporate announcement by Jiangsu Hengrui Medicine Co., Ltd. (stock code 600276) regarding its subsidiary receiving a clinical trial approval notice from the National Medical Products Administration. It provides details on the drug, the approval process, and risk reminders. This is not a financial report, earnings release, management change notice, or AGM material. It is a regulatory disclosure of a non-financial matter (drug approval) required under listing rules. Hence, it falls under general Regulatory Filings (RNS).
2026-05-14 Chinese
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jiangsu Hengrui Medicine Co., Ltd. regarding the receipt of a drug clinical trial approval notice from the National Medical Products Administration. It details the drug name, approval for clinical trials, and risk warnings related to the drug development process. The document is short (753 characters) and serves as an official announcement of regulatory approval rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-05-08 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.